186 related articles for article (PubMed ID: 37274644)
21. The effect of use of pyridostigmine and requirement of vecuronium in patients with myasthenia gravis.
Tripathi M; Kaushik S; Dubey P
J Postgrad Med; 2003; 49(4):311-4; discussion 314-5. PubMed ID: 14699228
[TBL] [Abstract][Full Text] [Related]
22. One-year follow-up of disease burden and medication changes in patients with myasthenia gravis: From the MG Patient Registry.
Lee I; Leach JM; Aban I; McPherson T; Duda PW; Cutter G
Muscle Nerve; 2022 Oct; 66(4):411-420. PubMed ID: 35673964
[TBL] [Abstract][Full Text] [Related]
23. Incidence, economic burden, and treatment of acute respiratory tract infection in hematopoietic stem cell transplantation recipients using real world data in Japan: a retrospective claims data analysis.
Wattanakamolkul K; Nakayama Y
J Med Econ; 2022; 25(1):870-879. PubMed ID: 35703058
[TBL] [Abstract][Full Text] [Related]
24. The impact of SARS-CoV-2 immunization on COVID-19 disease course in people with myasthenia gravis.
Bakirtzis C; Boziki MK; Karakasi MV; Moysiadis T; Grigoriadis N
Muscle Nerve; 2023 May; 67(5):412-416. PubMed ID: 36814101
[TBL] [Abstract][Full Text] [Related]
25. Canadian administrative health data can identify patients with myasthenia gravis.
Breiner A; Young J; Green D; Katzberg HD; Barnett C; Bril V; Tu K
Neuroepidemiology; 2015; 44(2):108-13. PubMed ID: 25765451
[TBL] [Abstract][Full Text] [Related]
26. Myasthenia gravis epidemiology in a national cohort; combining multiple disease registries.
Andersen JB; Heldal AT; Engeland A; Gilhus NE
Acta Neurol Scand Suppl; 2014; (198):26-31. PubMed ID: 24588503
[TBL] [Abstract][Full Text] [Related]
27. Myasthenia gravis-treatment and severity in nationwide cohort.
Sobieszczuk E; Napiórkowski Ł; Szczudlik P; Kostera-Pruszczyk A
Acta Neurol Scand; 2022 Apr; 145(4):471-478. PubMed ID: 34981830
[TBL] [Abstract][Full Text] [Related]
28. Rituximab Therapy in the Treatment of Juvenile Myasthenia Gravis: The French Experience.
Molimard A; Gitiaux C; Barnerias C; Audic F; Isapof A; Walther-Louvier U; Cances C; Espil-Taris C; Davion JB; Quijano-Roy S; Grisel C; Chabrol B; Desguerre I
Neurology; 2022 Jun; 98(23):e2368-e2376. PubMed ID: 35314497
[TBL] [Abstract][Full Text] [Related]
29. Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
; Busco S; Buzzoni C; Mallone S; Trama A; Castaing M; Bella F; Amodio R; Bizzoco S; Cassetti T; Cirilli C; Cusimano R; De Angelis R; Fusco M; Gatta G; Gennaro V; Giacomin A; Giorgi Rossi P; Mangone L; Mannino S; Rossi S; Pierannunzio D; Tavilla A; Tognazzo S; Tumino R; Vicentini M; Vitale MF; Crocetti E; Dal Maso L
Epidemiol Prev; 2016; 40(1 Suppl 2):1-120. PubMed ID: 26951748
[TBL] [Abstract][Full Text] [Related]
30. Real-World Evidence on Disease Burden and Economic Impact of Sickle Cell Disease in Italy.
De Franceschi L; Castiglioni C; Condorelli C; Valsecchi D; Premoli E; Fiocchi C; Perrone V; Esposti LD; Forni GL; On Behalf Of The GREATalyS Study Group
J Clin Med; 2022 Dec; 12(1):. PubMed ID: 36614918
[TBL] [Abstract][Full Text] [Related]
31. The natural history and ophthalmic involvement in childhood myasthenia gravis at the hospital for sick children.
Mullaney P; Vajsar J; Smith R; Buncic JR
Ophthalmology; 2000 Mar; 107(3):504-10. PubMed ID: 10711889
[TBL] [Abstract][Full Text] [Related]
32. Socio-Economic Burden of Myasthenia Gravis: A Cost-of-Illness Study in Bulgaria.
Ignatova V; Kostadinov K; Vassileva E; Muradyan N; Stefanov G; Iskrov G; Stefanov R
Front Public Health; 2022; 10():822909. PubMed ID: 35309194
[TBL] [Abstract][Full Text] [Related]
33. Major review: the clinical spectrum of pediatric myasthenia gravis: blepharoptosis, ophthalmoplegia and strabismus. A report of 14 cases.
McCreery KM; Hussein MA; Lee AG; Paysse EA; Chandran R; Coats DK
Binocul Vis Strabismus Q; 2002; 17(3):181-6. PubMed ID: 12171588
[TBL] [Abstract][Full Text] [Related]
34. Ocular myasthenia gravis in an academic neuro-ophthalmology clinic: clinical features and therapeutic response.
Mittal MK; Barohn RJ; Pasnoor M; McVey A; Herbelin L; Whittaker T; Dimachkie M
J Clin Neuromuscul Dis; 2011 Sep; 13(1):46-52. PubMed ID: 22361625
[TBL] [Abstract][Full Text] [Related]
35. Economic burden of diverticular disease: An observational analysis based on real world data from an Italian region.
Mennini FS; Sciattella P; Marcellusi A; Toraldo B; Koch M
Dig Liver Dis; 2017 Sep; 49(9):1003-1008. PubMed ID: 28663067
[TBL] [Abstract][Full Text] [Related]
36. Preanesthetic train-of-four fade predicts the atracurium requirement of myasthenia gravis patients.
Mann R; Blobner M; Jelen-Esselborn S; Busley R; Werner C
Anesthesiology; 2000 Aug; 93(2):346-50. PubMed ID: 10910480
[TBL] [Abstract][Full Text] [Related]
37. Epidemiology and treatment of myasthenia gravis: a retrospective study using a large insurance claims dataset in Germany.
Mevius A; Jöres L; Biskup J; Heidbrede T; Mahic M; Wilke T; Maywald U; Lehnerer S; Meisel A
Neuromuscul Disord; 2023 Apr; 33(4):324-333. PubMed ID: 36921445
[TBL] [Abstract][Full Text] [Related]
38. The Epidemiology, Treatment Patterns and Economic Burden of Different Phenotypes of Multiple Sclerosis in Italy: Relapsing-Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis.
Perrone V; Veronesi C; Giacomini E; Citraro R; Dell'Orco S; Lena F; Paciello A; Resta AM; Nica M; Ritrovato D; Degli Esposti L
Clin Epidemiol; 2022; 14():1327-1337. PubMed ID: 36387930
[TBL] [Abstract][Full Text] [Related]
39. Myasthenia gravis requiring pyridostigmine treatment in a national population cohort.
Andersen JB; Engeland A; Owe JF; Gilhus NE
Eur J Neurol; 2010 Dec; 17(12):1445-50. PubMed ID: 20491896
[TBL] [Abstract][Full Text] [Related]
40. Healthcare resource utilization by patients with treatment-refractory myasthenia gravis in England.
Harris L; Graham S; MacLachlan S; Exuzides A; Jacob S
J Med Econ; 2019 Jul; 22(7):691-697. PubMed ID: 30841772
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
